Novo Nordisk, Novartis Heart Drugs Fail in Trials — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Pharma industry invested billions developing drugs heralded as the next era in heart disease treatment, with two large clinical trials ultimately failing according to STAT's Readout LOUD podcast.
- Novo Nordisk and Novartis each developed one of the drugs involved in the two failed large clinical trials discussed on the episode.
- Ethan Weiss, cardiologist and biotech entrepreneur, joins the podcast to analyze the surprising trial failures and their long-term implications for new heart medicine development.
- The episode also recaps a spurt of FDA drug approvals during the podcast's hiatus and previews the next big thing in cancer treatment from Merck and Moderna.
Why it matters: Two anchor heart drug programs from Novo Nordisk and Novartis failed after billions in pharma investment, and STAT's Readout LOUD devotes an episode to what the collapses mean for heart drug development. With two of the field's most-watched cardiovascular programs failing in large trials, the episode directly grapples with the central question of which scientific approaches can deliver the next generation of heart treatments.
Ask SkimNews
